FDA Expands Social Media Monitoring to Track U.S. Cannabis Consumer Trends

The U.S. Food and Drug Administration (FDA) is significantly ramping up its efforts to understand how Americans use cannabis, CBD, and other emerging products by seeking external data and analytics firms to monitor public social media conversations, conduct consumer surveys, and gather market intelligence. According to High Times, the FDA’s new request for quotes outlines an ambitious plan to systematically analyze what people are buying, why they use cannabis, and how they talk about these experiences online

This initiative comes as the cannabis landscape in the United States grows increasingly complex, with medical cannabis legal in most states and adult-use marijuana permitted in nearly half. The resulting patchwork of regulations has led to vast differences in cannabis consumption patterns, product preferences, and reasons for use. The FDA’s focus goes far beyond product formats, delving into motivations, dosages, symptoms addressed, and the contexts in which cannabis is consumed

The FDA’s interest in detailed cannabis consumer data is not new. Back in 2022, the agency issued a call for small businesses to help collect and analyze data from social media, e-commerce sites, and even the dark web, employing machine learning and natural-language processing to spot emerging trends and potential adverse events. The 2018 Farm Bill, which removed hemp with less than 0.3% delta-9 THC from the federal definition of marijuana, sparked a boom in hemp-derived products and highlighted major knowledge gaps for regulators

The latest request, set to run from September 2026 through September 2027, seeks to combine social listening on platforms like TikTok, Instagram, and Reddit with detailed surveys of dispensary shoppers and broader consumer groups. The FDA is looking for technology that can continuously collect and structure cannabis-related online conversations, identifying product mentions, ingredient discussions, user claims, and sentiment. According to the agency, this data will help "address knowledge gaps on cannabis, cannabidiol (CBD), and emerging products and help inform work on policy and regulation, education and outreach, and compliance activities."

Importantly, the FDA’s request emphasizes public social media data, not private messages, and aims to filter information by attributes such as age group, sex, and consumer persona using AI models. Market intelligence will also cover CBD and other non-intoxicating products, tracking market size, leading brands, and product types. The planned contract is modeled after services provided by firms like Brightfield Group, which specialize in cannabis market research and social analytics

OG Lab notes that the FDA’s comprehensive approach signals a shift toward data-driven regulation and consumer education in the evolving U.S. cannabis market. As regulators, researchers, and businesses gain more granular insights into how Americans use cannabis, the industry could see more tailored policies and safer, more effective products. For consumers, this development may bring both improved information and a new level of scrutiny to public cannabis discourse